Regenerex Pharma (RGPX) Net Cash Flow (2010 - 2025)

Regenerex Pharma (RGPX) has 14 years of Net Cash Flow data on file, last reported at -$121853.0 in Q3 2025.

• Net Cash Flow for Q3 2025 came in at -$121853.0, down 41546.6% year-over-year; the trailing twelve-month figure through Sep 2025 was $51511.0 (up 990.27% YoY), and the FY2025 annual result was $652653.0, up 85637.75% from the prior year.
• Net Cash Flow grew to -$121853.0 in Q3 2025 per RGPX's latest filing, from -$480595.0 in the prior quarter.
• Over five years, Net Cash Flow peaked at $653915.0 in Q1 2025 and troughed at -$480595.0 in Q2 2025.
• A 5-year average of $3189.5 and a median of -$12.0 in 2023 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 8837.51% in 2025 and fell as far as 129092.2% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $244.0 in 2021, then surged by 708.2% to $1972.0 in 2022, then declined by 9.94% to $1776.0 in 2023, then plunged by 97.52% to $44.0 in 2024, then tumbled by 277038.64% to -$121853.0 in 2025.
• Business Quant data shows RGPX's Net Cash Flow at -$121853.0 in Q3 2025, -$480595.0 in Q2 2025, and $653915.0 in Q1 2025.